EDN1 and Parkinson disease: This body of work identifies ET-1 as a pivotal therapeutic target in Parkinson’s disease PD-associated neurovascular dysfunction, while highlighting NSC-based interventions as promising strategies for achieving comprehensive repair through neuroprotection, angiogenic modulation, and synaptic network reintegration.